Curaleaf Holdings, Inc. has announced its financial results for the third quarter of 2026, showcasing record revenue and robust profitability. The company reported net revenue of $353 million, an 11% increase compared to the same period last year. This strong performance underscores Curaleaf's strategic execution in a competitive market.

Curaleaf Holdings, Inc., a leading provider in the medicinal chemicals and botanical products sector, operates primarily in the cannabis industry. The company trades under the ticker CURLF on the OTC exchange and is classified under the SIC code 2833. Curaleaf has been actively involved in expanding its operations and enhancing its market position through various initiatives.

The recent SEC filing indicates that on November 3, 2026, Curaleaf released its third-quarter financial results. The report highlighted a net revenue of $353 million for the quarter ended September 30, 2026, with international revenue contributing $59 million. The adjusted gross profit margin was reported at 49%, and adjusted EBITDA reached $78 million.

According to the filing, Chairman and CEO Boris Jordan stated, “We are building the global leader in cannabis, and our third-quarter results provide further evidence that our strategy is delivering.” The company experienced growth in both domestic and international segments, with the U.S. business sustaining momentum from previous quarters.

These results may impact various stakeholders, including investors, employees, and competitors in the medicinal cannabis space. Curaleaf's strong financial performance could enhance investor confidence and influence market dynamics within the industry.

Looking ahead, the filing does not specify any immediate next steps or upcoming events related to this announcement.